Similar studies for GEO DataSets (Select 5267) - GEO DataSets

Select item 52671.

Cyclin-dependent kinase inhibitor R547 effect on prostate cancer cell line: dose response and time course

Analysis of DU145 prostate cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 3 agent, 4 dose, 4 time sets

Platform:: GPL570
Series:: GSE15392
45 Samples

Download data: CEL

DataSet

Accession:: GDS5267

ID:: 5267

Select item 2000153962.

Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
156 Samples

Download data: CEL

Series

Accession:: GSE15396

ID:: 200015396

Select item 2000153953.

HCT116 tumor cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5268
Platform:: GPL570
74 Samples

Download data: CEL

Series

Accession:: GSE15395

ID:: 200015395

Select item 2000153924.

DU145 tumor cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5267
Platform:: GPL570
45 Samples

Download data: CEL

Series

Accession:: GSE15392

ID:: 200015392

Select item 2000153895.

Peripheral blood mononuclear cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5266
Platform:: GPL570
37 Samples

Download data: CEL

Series

Accession:: GSE15389

ID:: 200015389

Select item 52686.

Cyclin-dependent kinase inhibitor R547 effect on colon cancer cell line: dose response and time course

Analysis of HCT116 colon cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and DU145 cells (GDS5267) to identify pharmacodynamic biomarkers for R547.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 3 agent, 4 dose, 6 time sets

Platform:: GPL570
Series:: GSE15395
74 Samples

Download data: CEL

DataSet

Accession:: GDS5268

ID:: 5268

Select item 52667.

Cyclin-dependent kinase inhibitor R547 effect on peripheral blood mononuclear cells: dose response and time course

Analysis of peripheral blood mononuclear cells treated with CDK inhibitor R547 at 2 doses for 2 and 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from DU145 (GDS5267) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 3 agent, 3 dose, 3 time sets

Platform:: GPL570
Series:: GSE15389
37 Samples

Download data: CEL

DataSet

Accession:: GDS5266

ID:: 5266

Select item 2000185538.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study

(Submitter supplied) Microarray analysis of transcriptional changes in biopsies of solid tumors from patients treated in a Phase I study with the Cdk inhibitor PHA-793887.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
7 Samples

Download data: TXT

Series

Accession:: GSE18553

ID:: 200018553

Select item 2000899359.

Identification of potential ABBV-075 responsive markers in mouse whole blood

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated mouse whole blood samples

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL1261
15 Samples

Download data: CEL

Series

Accession:: GSE89935

ID:: 200089935

Select item 20008993410.

Identification of potential ABBV-075 responsive markers in mouse skin

(Submitter supplied) Determination of transcriptional alterations in skin samples from ABBV-075 treated mice

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL1261
11 Samples

Download data: CEL

Series

Accession:: GSE89934

ID:: 200089934

Select item 20008993311.

Identification of potential ABBV-075 responsive markers in human PBMCs

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated human PBMC samples

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL571
10 Samples

Download data: CEL

Series

Accession:: GSE89933

ID:: 200089933

Select item 20008993212.

Identification of genes that are modulated by BET inhibitors in cancer cells to identify robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissue

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL571
36 Samples

Download data: CEL

Series

Accession:: GSE89932

ID:: 200089932

Select item 20008624513.

Contribution of BET proteins to androgen (DHT)-stimulated gene expression program

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs. Here we tested the hypothesis that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clinical progression, including the Androgen Receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
8 Samples

Download data: CEL

Series

Accession:: GSE86245

ID:: 200086245

GEO DataSets

Functional Genomics Studies

Result Filters

Entry type

Organism

Study type

Author

Attribute name

Publication dates

Custom date range

Additional filters

Send to:

Links from GEO DataSets

Items: 13

Send to:

Supplemental Content

Find related data

Important Links

Recent activity